Aker BioMarine ASAOSL: AKBM

AKBM: Q1 2025 delivered strong revenue and EBITDA growth, with robust outlook and mitigated risks

· Issued by Aker BioMarine ASA

Q1 2025 saw 5% revenue growth and a 59% rise in adjusted EBITDA, led by strong human health segment performance and cost control. New clinical trials, retail partnerships, and market expansion underpin a positive outlook, with risks from tariffs and market timing mitigated.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Aker BioMarine ASA on 6ix

In the deck

Story so far

Earlier from Aker BioMarine

Later from Aker BioMarine

All Aker BioMarine news releases